PISCATAWAY, N.J., May 10, 2010 -Internationally recognized biology contract research organization GenScript USA Inc. participated in the BIT Life Sciences’ 2nd Annual International Congress of Antibodies (ICA) during Mar 24–26, 2010. Dr. Oliver Zhang, the Director of Antibody Drug Development at GenScript, gave a presentation on FASEBA technology during the congress.
During the presentation, Dr. Zhang introduced the FASEBA technology that is used to obtain information on three key features—expression levels, biophysical properties, and affinities of a large number of proteins at early stage without protein purification.
FASEBA technology was developed by NRC, where Dr. Zhang had been working for about 10 years. This technology is licensed to GenScript now. GenScript has intention to establish FASEBA platform in the near future to fulfill the demands of detecting proteins’ expression levels, biophysical properties, and affinities to facilitate the process of antibody drug development.
GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
